Gökhan Temiz
Research Subjects
Gökhan Temiz has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Uğur Yalçın
ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, NEFROLOJİ BİLİM DALI
1 shared publication Ali Cem Akpınar
Dr. Lütfi Kırdar Kartal Training and Research Hospital
1 shared publication- Caglar Kuas
Department of Emergency Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey
1 shared publication - Deniz Filinte
Marmara Univ, Fac Med, Dept Pathol, Istanbul, Turkey
1 shared publication Emre Güvercin
Dr. Lütfi Kırdar Kartal Training and Research Hospital
1 shared publication- Engin Ozakin
Department of Emergency Medicine, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye
1 shared publication
Latest Publications
- 4 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (5) , 766-773
Incidence and Risk Factors of Contrast-Induced Nephropathy in Emergency Department Patients Undergoing Contrast-Enhanced CT
Contrast-induced nephropathy (CIN) is a serious complication following the administration of iodinated contrast media, contributing significantly to hospital-acquired acute kidney injury. Contrast-induced nephropathy is defined as either a ≥25% increase from baseline creatinine levels or an absolute increase >0.5 mg/dL, within 48–72 hours after contrast media administration. This study evaluated CIN incidence and associated risk factors in emergency department (ED) patients undergoing contrast-enhanced CT. A prospective observational study was conducted at a tertiary-care ED (June 2013–September 2014). Adults (≥18 years) undergoing CT were enrolled, excluding those with baseline creatinine >1.2 mg/dL, acute kidney injury, or hemodynamic instability. Of the contrast-enhanced CT group (n=171), 14 patients (8.1%) developed CIN, whereas in the non-contrast CT group (n=171), 12 patients (7.0%) developed nephropathy. Hospitalization (p=0.030), advanced age (p=0.026), anemia (p=0.045), leukocytosis (p=0.005), and reduced GFR (p=0.028) were identified as risk factors for contrast-induced nephropathy. In the non-contrast group, anemia (p=0.003), hospitalization (n=9; p=0.039), and leukocytosis (p=0.007) were identified as risk factors for nephropathy. No cases of nephropathy was observed in patients discharged from the ED in either group. Contrast media did not significantly increase nephropathy risk in ED patients with normal renal function. However, older age, anemia, and hospitalization identified high-risk subgroups. Prophylactic measures showed no clear benefit, possibly due to ED time constraints. Vigilance is recommended for elderly and hospitalized patients, with renal monitoring following contrast administration.
- 4 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (5) , 766-773
Incidence and Risk Factors of Contrast-Induced Nephropathy in Emergency Department Patients Undergoing Contrast-Enhanced CT
Contrast-induced nephropathy (CIN) is a serious complication following the administration of iodinated contrast media, contributing significantly to hospital-acquired acute kidney injury. Contrast-induced nephropathy is defined as either a ≥25% increase from baseline creatinine levels or an absolute increase >0.5 mg/dL, within 48–72 hours after contrast media administration. This study evaluated CIN incidence and associated risk factors in emergency department (ED) patients undergoing contrast-enhanced CT. A prospective observational study was conducted at a tertiary-care ED (June 2013–September 2014). Adults (≥18 years) undergoing CT were enrolled, excluding those with baseline creatinine >1.2 mg/dL, acute kidney injury, or hemodynamic instability. Of the contrast-enhanced CT group (n=171), 14 patients (8.1%) developed CIN, whereas in the non-contrast CT group (n=171), 12 patients (7.0%) developed nephropathy. Hospitalization (p=0.030), advanced age (p=0.026), anemia (p=0.045), leukocytosis (p=0.005), and reduced GFR (p=0.028) were identified as risk factors for contrast-induced nephropathy. In the non-contrast group, anemia (p=0.003), hospitalization (n=9; p=0.039), and leukocytosis (p=0.007) were identified as risk factors for nephropathy. No cases of nephropathy was observed in patients discharged from the ED in either group. Contrast media did not significantly increase nephropathy risk in ED patients with normal renal function. However, older age, anemia, and hospitalization identified high-risk subgroups. Prophylactic measures showed no clear benefit, possibly due to ED time constraints. Vigilance is recommended for elderly and hospitalized patients, with renal monitoring following contrast administration.
- Open Access
- 16 October 2020
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(68),p. 29-37
Does erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?
Anemia is a common complication of chronic kidney disease (CKD). The most common cause of anemia in CKD is erythropoietin deficiency; and the most important cause of mortality in CKD patients is atherosclerotic vascular complications which are associated with endothelial damage. One of the methods evaluating vascular integrity is the cytometric measurement of circulating endothelial cells and endothelial progenitor cells in peripheral blood. The study aimed to investigate the effects of erythropoietin therapy on endothelial dysfunction by evaluating circulating endothelial cells and endothelial progenitor cells in peripheral blood using the technique of flow cytometry. Methods. A total of 55 hemodialysis patients were evaluated in three groups; those having erythropoietin therapy for at least last 3 months (n = 20) / not having erythropoietin for at least the last 3 months (n = 20) and the patients who started erythropoietin treatment during the study (n = 5). The control group consisted of 20 people. Blood values of the 3rd Group were investigated three times as baseline, 2nd week and 8th week CD34 +, CD105 + cells were evaluated as activated circulating endothelial cells; CD133 +, CD146 + cells were evaluated as activated endothelial progenitor cells. Results. There was no difference between the patients and healthy individuals in terms of circulating endothelial cells and endothelial progenitor cells. In the third group, no differences were observed in circulating endothelial cells / endothelial progenitor cell levels at baseline / 2nd and 8th weeks. There was no correlation between erythropoietin and circulating endothelial cells / endothelial progenitor cells. Conclusion. A correlation is not available between the therapeutic doses of erythropoietin used in hemodialysis patients and circulating endothelial cells / endothelial progenitor cell levels; supratherapeutic doses could change the results.
- 16 October 2020
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(68),p. 29-37
Open AccessDoes erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?
Anemia is a common complication of chronic kidney disease (CKD). The most common cause of anemia in CKD is erythropoietin deficiency; and the most important cause of mortality in CKD patients is atherosclerotic vascular complications which are associated with endothelial damage. One of the methods evaluating vascular integrity is the cytometric measurement of circulating endothelial cells and endothelial progenitor cells in peripheral blood. The study aimed to investigate the effects of erythropoietin therapy on endothelial dysfunction by evaluating circulating endothelial cells and endothelial progenitor cells in peripheral blood using the technique of flow cytometry. Methods. A total of 55 hemodialysis patients were evaluated in three groups; those having erythropoietin therapy for at least last 3 months (n = 20) / not having erythropoietin for at least the last 3 months (n = 20) and the patients who started erythropoietin treatment during the study (n = 5). The control group consisted of 20 people. Blood values of the 3rd Group were investigated three times as baseline, 2nd week and 8th week CD34 +, CD105 + cells were evaluated as activated circulating endothelial cells; CD133 +, CD146 + cells were evaluated as activated endothelial progenitor cells. Results. There was no difference between the patients and healthy individuals in terms of circulating endothelial cells and endothelial progenitor cells. In the third group, no differences were observed in circulating endothelial cells / endothelial progenitor cell levels at baseline / 2nd and 8th weeks. There was no correlation between erythropoietin and circulating endothelial cells / endothelial progenitor cells. Conclusion. A correlation is not available between the therapeutic doses of erythropoietin used in hemodialysis patients and circulating endothelial cells / endothelial progenitor cell levels; supratherapeutic doses could change the results.
- 29 December 2015
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 40 (1) , 164-173
Effects of Different Concentrations of Injectable Collagenase Enzyme on Capsular Tissue Around Silicone Implants: A Preliminary Experimental Study for the Development of a New Treatment Strategy
In recent studies, collagen organization was blamed for the formation of capsular contracture which is still a challenging problem after silicone implant-based breast operations. In this study, effects of different concentrations of collagenase enzyme derived from Clostridium histolyticum on the capsular tissue formation around the silicone implants were investigated. The injectable form of collagenase has a routine clinical use in the treatment of both Dupuytren’s and Peyronie’s diseases. Thirty-two Wistar albino rats were randomized into four groups. A 2 × 1 × 0.3-cm-sized silicone block was inserted inside a dorsal subcutaneous pocket in all groups. After 2 months of insertion, capsule thicknesses around the implants were detected under ultrasonography. This was followed by injection of isotonic saline, 150, 300, and 600 IU in Gr-1, 2, 3, and 4, respectively. All the animals were sacrificed at the end of the first week for histologic sampling to determine fibroblast proliferation, vessel density of the tissue, necrosis, edema, inflammation, and capsule thickness. All the data were statistically analyzed using Kruskal–Wallis and Mann–Whitney U tests and compared for significance of the results. There was no significant difference in terms of capsule thinning between the 300 and 600 IU groups but in both groups thinning was significantly higher than the sham group. In the 150 IU group there was no significant thinning as compared to the sham group (p > 0.05). However, complications such as skin necrosis, infection, and seroma formation were seen only in the 600 IU injection group. The optimal safe and effective dose of the enzyme was accepted as 300 IU. The 300 IU injection provided up to 89 % thinning in the capsule tissue. There was thinning of the collagen bundles parallel to capsule thickness. In the 600 IU group, micro-pores were encountered at the thinnest points. However, the late results and recurrence rates of capsular contracture were not included in this study; collagenase seemed effective for the reduction of capsular tissue around the implants. This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- 29 December 2015
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 40 (1) , 164-173
Effects of Different Concentrations of Injectable Collagenase Enzyme on Capsular Tissue Around Silicone Implants: A Preliminary Experimental Study for the Development of a New Treatment Strategy
In recent studies, collagen organization was blamed for the formation of capsular contracture which is still a challenging problem after silicone implant-based breast operations. In this study, effects of different concentrations of collagenase enzyme derived from Clostridium histolyticum on the capsular tissue formation around the silicone implants were investigated. The injectable form of collagenase has a routine clinical use in the treatment of both Dupuytren’s and Peyronie’s diseases. Thirty-two Wistar albino rats were randomized into four groups. A 2 × 1 × 0.3-cm-sized silicone block was inserted inside a dorsal subcutaneous pocket in all groups. After 2 months of insertion, capsule thicknesses around the implants were detected under ultrasonography. This was followed by injection of isotonic saline, 150, 300, and 600 IU in Gr-1, 2, 3, and 4, respectively. All the animals were sacrificed at the end of the first week for histologic sampling to determine fibroblast proliferation, vessel density of the tissue, necrosis, edema, inflammation, and capsule thickness. All the data were statistically analyzed using Kruskal–Wallis and Mann–Whitney U tests and compared for significance of the results. There was no significant difference in terms of capsule thinning between the 300 and 600 IU groups but in both groups thinning was significantly higher than the sham group. In the 150 IU group there was no significant thinning as compared to the sham group (p > 0.05). However, complications such as skin necrosis, infection, and seroma formation were seen only in the 600 IU injection group. The optimal safe and effective dose of the enzyme was accepted as 300 IU. The 300 IU injection provided up to 89 % thinning in the capsule tissue. There was thinning of the collagen bundles parallel to capsule thickness. In the 600 IU group, micro-pores were encountered at the thinnest points. However, the late results and recurrence rates of capsular contracture were not included in this study; collagenase seemed effective for the reduction of capsular tissue around the implants. This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .